603882 金域医学
已收盘 08-17 15:00:00
资讯
新帖
简况
金域医学新注册《方法学比对与正确度分析系统V1.1.2》项目的软件著作权
证券之星 · 08-14
金域医学新注册《方法学比对与正确度分析系统V1.1.2》项目的软件著作权
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票与股票期权激励计划首次授予激励对象名单（首次授予日）的核查意见》
证券之星 · 08-10
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票与股票期权激励计划首次授予激励对象名单（首次授予日）的核查意见》
每周股票复盘：金域医学（603882）推210万限制性股票激励
证券之星 · 08-09
每周股票复盘：金域医学（603882）推210万限制性股票激励
金域医学（603882）披露关于向激励对象首次授予限制性股票与股票期权的公告，8月7日股价上涨3.35%
证券之星 · 08-07
金域医学（603882）披露关于向激励对象首次授予限制性股票与股票期权的公告，8月7日股价上涨3.35%
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告》
证券之星 · 08-05
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告》
金域医学（603882）披露以集中竞价交易方式回购公司股份的进展公告，8月3日股价下跌0.9%
证券之星 · 08-03
金域医学（603882）披露以集中竞价交易方式回购公司股份的进展公告，8月3日股价下跌0.9%
金域医学：依托30PB高质量医检数据资源形成核心数据服务差异化竞争优势
证券之星 · 08-03
金域医学：依托30PB高质量医检数据资源形成核心数据服务差异化竞争优势
金域医学：制定2026年度“提质增效重回报”行动方案
证券之星 · 08-03
金域医学：制定2026年度“提质增效重回报”行动方案
每周股票复盘：金域医学（603882）2026年推股权激励计划
证券之星 · 08-02
每周股票复盘：金域医学（603882）2026年推股权激励计划
金域医学：持续推动实验室自动化、智能化升级
证券之星 · 07-31
金域医学：持续推动实验室自动化、智能化升级
金域医学：(XN)X1=2条，(1-22)X2=44条，共46条染色体
证券之星 · 07-31
金域医学：(XN)X1=2条，(1-22)X2=44条，共46条染色体
金域医学：2025年经营活动现金流量净额为120,200.93万元
证券之星 · 07-31
金域医学：2025年经营活动现金流量净额为120,200.93万元
股市必读：新发布《广州金域医学检验集团股份有限公司2026年第二次临时股东会决议公告》
证券之星 · 07-31
股市必读：新发布《广州金域医学检验集团股份有限公司2026年第二次临时股东会决议公告》
金域医学（603882）披露2026年限制性股票与股票期权激励计划草案，7月30日股价下跌1.02%
证券之星 · 07-30
金域医学（603882）披露2026年限制性股票与股票期权激励计划草案，7月30日股价下跌1.02%
每周股票复盘：金域医学（603882）推2026年股权激励计划
证券之星 · 07-26
每周股票复盘：金域医学（603882）推2026年股权激励计划
金域医学（603882）披露2026年限制性股票与股票期权激励计划草案，7月24日股价下跌2.07%
证券之星 · 07-24
金域医学（603882）披露2026年限制性股票与股票期权激励计划草案，7月24日股价下跌2.07%
广东167家公司发布半年业绩预告，近半数净利润高速增长
第一财经 · 07-22
广东167家公司发布半年业绩预告，近半数净利润高速增长
每周股票复盘：金域医学（603882）预盈1.7亿至2.2亿元
证券之星 · 07-19
每周股票复盘：金域医学（603882）预盈1.7亿至2.2亿元
金域医学新注册《金域医学项目对照管理系统V1.1.3》项目的软件著作权
证券之星 · 07-18
金域医学新注册《金域医学项目对照管理系统V1.1.3》项目的软件著作权
金域医学上半年净利预增300%至359%；国际医学上半年预计亏损6300万元至6600万元 | 医药早参
每日经济新闻 · 07-14
金域医学上半年净利预增300%至359%；国际医学上半年预计亏损6300万元至6600万元 | 医药早参
加载更多
公司概况
公司名称：
广州金域医学检验集团股份有限公司
所属行业：
卫生
上市日期：
2017-09-08
主营业务：
广州金域医学检验集团股份有限公司的主营业务是第三方医学检验及病理诊断业务。公司的主要产品是医学诊断服务、销售诊断产品、健康体检业务、冷链物流服务。公司参与获批国家科技重大专项4项，国家“战略性科技创新合作”重点专项1项。全年发表论文共101篇，其中SCI论文32篇，学术影响力持续提升。
发行价格：
6.93
{"stockData":{"symbol":"603882","market":"SH","secType":"STK","nameCN":"金域医学","latestPrice":29.05,"timestamp":1786950000000,"preClose":30.06,"halted":0,"volume":12094727,"delay":0,"changeRate":-0.0336,"floatShares":459999999,"shares":463000000,"eps":-0.2217,"marketStatus":"已收盘","change":-1.01,"latestTime":"08-17 15:00:00","open":30.06,"high":30.06,"low":28.71,"amount":351000000,"amplitude":0.0449,"askPrice":29.05,"askSize":190,"bidPrice":29.04,"bidSize":425,"shortable":0,"etf":0,"ttmEps":-0.2217,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787016600000},"marketStatusCode":5,"adr":0,"adjPreClose":30.06,"symbolType":"stock","openAndCloseTimeList":[[1786930200000,1786937400000],[1786942800000,1786950000000]],"highLimit":33.07,"lowLimit":27.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":463258275,"isCdr":false,"pbRate":2.12,"roa":"--","roe":"0.65%","epsLYR":-0.37,"committee":-0.306098,"marketValue":13458000000,"turnoverRate":0.0263,"status":1,"floatMarketCap":13367000000},"requestUrl":"/m/hq/s/603882","defaultTab":"news","newsList":[{"id":"2659161440","title":"金域医学新注册《方法学比对与正确度分析系统V1.1.2》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2659161440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659161440?lang=zh_cn&edition=full","pubTime":"2026-08-14 02:23","pubTimestamp":1786645395,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金域医学（603882）新注册了《方法学比对与正确度分析系统V1.1.2》项目的软件著作权。今年以来金域医学新注册软件著作权37个，较去年同期减少了41.27%。结合公司2025年年报财务数据，2025年公司在研发方面投入了3.41亿元，同比减14.78%。通过天眼查大数据分析，广州金域医学检验集团股份有限公司共对外投资了59家企业，参与招投标项目29次；财产线索方面有商标信息766条，专利信息223条，著作权信息198条；此外企业还拥有行政许可62个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0042","159180","BK0236","603882","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658047670","title":"股市必读：金域医学新发布《广州金域医学检验集团股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票与股票期权激励计划首次授予激励对象名单（首次授予日）的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658047670","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658047670?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:02","pubTimestamp":1786298537,"startTime":"0","endTime":"0","summary":"广州金域医学检验集团股份有限公司2026年限制性股票与股票期权激励计划首次授予激励对象名单金域医学公布2026年限制性股票与股票期权激励计划首次授予激励对象名单：李慧源获授限制性股票16.5606万股，马骥获授股票期权27.6008万份；40名中层管理人员合计获授限制性股票176.8788万股、股票期权294.7984万份；预留权益140.0000万股，占授予权益总数20.00%；本次授予权益总数700.0000万份，占公司总股本1.52%；激励对象不包括独立董事及持股5%以上股东及其关联人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0236","603882","BK0284","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658467538","title":"每周股票复盘：金域医学（603882）推210万限制性股票激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2658467538","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658467538?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:28","pubTimestamp":1786213693,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，金域医学报收于28.97元，较上周的27.76元上涨4.36%。本周，金域医学8月7日盘中最高价报29.36元。本周关注点公司公告汇总：金域医学向42名激励对象授予210万股限制性股票，授予价格12.78元/股。截至2026年7月31日，已累计回购676.88万股，占总股本1.46%，支付金额17,758.25万元，回购价格区间为23.36元/股至28.79元/股。本次授予权益总数合计700.0000万份，占公司总股本的1.52%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0284","BK0236","BK0042","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657264411","title":"金域医学（603882）披露关于向激励对象首次授予限制性股票与股票期权的公告，8月7日股价上涨3.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657264411","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657264411?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:25","pubTimestamp":1786112709,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，金域医学报收于28.97元，较前一交易日上涨3.35%，最新总市值为134.21亿元。近日，广州金域医学检验集团股份有限公司发布《关于向激励对象首次授予限制性股票与股票期权的公告》。公告显示，公司于2026年8月7日召开第四届董事会第十四次会议，确定向42名激励对象首次授予210万股限制性股票和350万份股票期权，授予日为2026年8月7日，限制性股票授予价格为12.78元/股，股票期权行权价格为25.55元/份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","BK0236","SG9999001069.SGD","603882","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563449","title":"股市必读：金域医学新发布《广州金域医学检验集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657563449?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:06","pubTimestamp":1785866775,"startTime":"0","endTime":"0","summary":"公司公告汇总：截至2026年7月31日，金域医学已累计回购676.88万股，支付金额17,758.25万元，回购进度达承诺下限的118.39%。公司公告汇总广州金域医学检验集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告2026年4月10日，公司董事会审议通过回购股份方案，拟以自有资金和自筹资金通过集中竞价交易方式回购股份，用于股权激励，回购金额不低于15,000万元不超过20,000万元，价格不超35.00元/股，期限为6个月。2026年7月单月回购15.5万股，支付415.88万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","603882","BK0042","BK0284","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656854377","title":"金域医学（603882）披露以集中竞价交易方式回购公司股份的进展公告，8月3日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656854377","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656854377?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:17","pubTimestamp":1785766652,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，金域医学报收于27.51元，较前一交易日下跌0.9%，最新总市值为127.44亿元。该股当日开盘27.76元，最高28.28元，最低27.42元，成交额达1.59亿元，换手率为1.25%。近日，广州金域医学检验集团股份有限公司发布《关于以集中竞价交易方式回购公司股份的进展公告》。2026年7月单月回购15.5万股，支付415.88万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0284","BK0042","603882","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656067326","title":"金域医学：依托30PB高质量医检数据资源形成核心数据服务差异化竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2656067326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656067326?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:33","pubTimestamp":1785742393,"startTime":"0","endTime":"0","summary":"请问公司是否计划依托域见医言大模型，为创新药企提供靶向药研发数据集、AI辅助临床分层、耐药机制分析等AI制药配套服务？后续有无向AI创新药研发服务商延伸的规划？公司依托30PB的高质量医检数据资源、数据治理能力、数据平台支撑能力，形成了核心数据服务层面的差异化竞争优势。公司将持续关注该领域的发展机遇，并依托数据资源和AI能力，积极探索相关的服务模式。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300014424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0236","603882","SG9999001069.SGD","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656329859","title":"金域医学：制定2026年度“提质增效重回报”行动方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2656329859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656329859?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:33","pubTimestamp":1785742385,"startTime":"0","endTime":"0","summary":"为推动公司投资价值提升，增强投资者回报，维护投资者利益，公司已制定《市值管理制度》，并制定了2026年度“提质增效重回报”行动方案。2026年，公司制定了2025年前三季度利润分配方案，向全体股东每10股派发现金红利8.8元（含税），共计派发现金红利约4.08亿元，于2026年2月5日实施完毕。截至2026年6月30日，本次回购方案公司已累计回购股份6,613,800股，占公司总股本的比例为1.43%，已支付的总金额为173,423,703.04元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300014414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","603882","SG9999001069.SGD","BK0236","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656331657","title":"每周股票复盘：金域医学（603882）2026年推股权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2656331657","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656331657?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:45","pubTimestamp":1785606315,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，金域医学报收于27.76元，较上周的25.97元上涨6.89%。本周关注点公司公告汇总：金域医学2026年第二次临时股东会通过2026年限制性股票与股票期权激励计划草案。广州金域医学检验集团股份有限公司对2026年限制性股票与股票期权激励计划内幕信息知情人在草案公告前六个月内买卖公司股票的情况进行了自查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0236","BK0042","BK0284","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655357442","title":"金域医学：持续推动实验室自动化、智能化升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2655357442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655357442?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:21","pubTimestamp":1785493278,"startTime":"0","endTime":"0","summary":"投资者提问：董秘您好，公司2026年核心战略为降本增效、数智化转型、实验室国产化替换，迈克生物智汇全链路智慧流水线可一站式降低试剂采购、人工运维综合成本，目前迈克已在多家三甲落地整线智慧实验室。请问公司是否对迈克整套智慧实验室方案开展调研？目前，公司正依托“AI IN ALL”战略和智慧实验室建设经验，持续推动实验室自动化、智能化升级，已在智慧实验室建设方面取得显著成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100032380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0236","BK0284","SG9999001069.SGD","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655357441","title":"金域医学：(XN)X1=2条，(1-22)X2=44条，共46条染色体","url":"https://stock-news.laohu8.com/highlight/detail?id=2655357441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655357441?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:21","pubTimestamp":1785493272,"startTime":"0","endTime":"0","summary":"证券之星消息，金域医学07月31日在投资者关系平台上答复投资者关心的问题。导致妊娠异常的因素很多，例如内分泌因素，免疫因素，子宫异常，环境因素和染色体问题等等。根据您所提及的染色体信息，经核验回复您：X1=2条，X2=44条，共46条染色体。公司始终严格遵守国内外相关技术规范与报告标准，检测报告格式及内容符合行业规范要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100032363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","603882","BK0284","BK0042","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655854357","title":"金域医学：2025年经营活动现金流量净额为120,200.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655854357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655854357?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:06","pubTimestamp":1785492397,"startTime":"0","endTime":"0","summary":"2025年，公司经营活动产生的现金流量净额为120,200.93万元，同比增加32.62%，现金流改善主要得益于以下原因：公司进一步加强现金流管理力度，应收账款回收进度改善明显；公司积极通过降本增效及数智化转型提升运营效率。2025年，公司严格遵循《企业会计准则》及相关规定进行会计处理，对应收账款按照账龄组合计提减值准备，年审会计师已出具标准无保留意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100030961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","603882","BK0236","BK0284","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655880010","title":"股市必读：新发布《广州金域医学检验集团股份有限公司2026年第二次临时股东会决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655880010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655880010?lang=zh_cn&edition=full","pubTime":"2026-07-31 02:40","pubTimestamp":1785436821,"startTime":"0","endTime":"0","summary":"广州金域医学检验集团股份有限公司关于公司2026年限制性股票与股票期权激励计划内幕信息知情人买卖公司股票情况的自查报告广州金域医学检验集团股份有限公司对2026年限制性股票与股票期权激励计划内幕信息知情人在草案公告前六个月内买卖公司股票的情况进行了自查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0284","BK0236","BK0042","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655964806","title":"金域医学（603882）披露2026年限制性股票与股票期权激励计划草案，7月30日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655964806","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655964806?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:39","pubTimestamp":1785422354,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，金域医学报收于27.14元，较前一交易日下跌1.02%，最新总市值为125.73亿元。该股当日开盘27.2元，最高27.66元，最低27.03元，成交额达1.48亿元，换手率为1.18%。近日，广州金域医学检验集团股份有限公司召开2026年第二次临时股东会，审议通过了《公司2026年限制性股票与股票期权激励计划（草案）》及其摘要、《2026年限制性股票与股票期权激励计划实施考核管理办法》以及提请股东会授权董事会办理本次激励计划相关事宜的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000040055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0284","BK0236","BK0042","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654057374","title":"每周股票复盘：金域医学（603882）推2026年股权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2654057374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654057374?lang=zh_cn&edition=full","pubTime":"2026-07-26 02:17","pubTimestamp":1785003430,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，金域医学报收于25.97元，较上周的26.37元下跌1.52%。本周，金域医学7月22日盘中最高价报27.48元。公司公告汇总：金域医学将召开2026年第二次临时股东会，审议2026年股权激励计划相关议案。公司公告汇总广州金域医学检验集团股份有限公司董事会薪酬与考核委员会对2026年限制性股票与股票期权激励计划首次授予激励对象名单的公示情况进行核查。薪酬委员会认为激励对象主体资格合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","603882","SG9999001069.SGD","BK0236","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088038","title":"金域医学（603882）披露2026年限制性股票与股票期权激励计划草案，7月24日股价下跌2.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653088038?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:28","pubTimestamp":1784903302,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，金域医学报收于25.97元，较前一交易日下跌2.07%，最新总市值为120.31亿元。该股当日开盘26.38元，最高27.0元，最低25.91元，成交额达1.43亿元，换手率为1.18%。近日，广州金域医学检验集团股份有限公司披露《公司2026年限制性股票与股票期权激励计划（草案）》及其摘要、《2026年限制性股票与股票期权激励计划实施考核管理办法》及提请股东会授权董事会办理本次激励计划相关事宜的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400042301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0284","BK0236","BK0042","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653026763","title":"广东167家公司发布半年业绩预告，近半数净利润高速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2653026763","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653026763?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:24","pubTimestamp":1784726663,"startTime":"0","endTime":"0","summary":"7月22日，第一财经从广东证监局了解到，截至目前，广东辖区已有167家上市公司披露了2026年上半年业绩预告，占辖区上市公司总数的36%。其中，近半数公司业绩高速增长，超三成公司持续盈利且净利润同比增速超50%，20家公司扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817622990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817622990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["002918","BK0188","002192","BK0077","BK0235","001389","002709","BK0182","LU2495084118.USD","002842","BK0042","EVS.SI","300014","002841","SG9999003461.SGD","BK0279","BK0007","BK0185","LU2929501877.USD","301377","600685","300438","BK0224","BK0005","BK0170","BK0229","000100","600428","LU0543330566.HKD","IE0005HP3H50.USD","LU0348766576.USD","BK0209","603268","LU1719994722.HKD","BK0155","002187","BK0024","LU1580142542.USD","LU0708995153.HKD","SG9999002950.SGD","688548","BK0126","000776","688183","LU2289578879.USD","603882","BK0242","BK0093","600183","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652728237","title":"每周股票复盘：金域医学（603882）预盈1.7亿至2.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652728237","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652728237?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:56","pubTimestamp":1784397372,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，金域医学报收于26.37元，较上周的24.62元上涨7.11%。本周，金域医学7月15日盘中最高价报29.29元。本周关注点来自业绩披露要点：金域医学预计2026年上半年归母净利润为1.7亿元至2.2亿元，同比扭亏为盈。来自公司公告汇总：公司拟实施2026年限制性股票与股票期权激励计划，授予权益总数700万股，占总股本1.51%。扣非后净利润预计盈利1.8亿元至2.3亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0284","BK0236","BK0042","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652282071","title":"金域医学新注册《金域医学项目对照管理系统V1.1.3》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2652282071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652282071?lang=zh_cn&edition=full","pubTime":"2026-07-18 02:08","pubTimestamp":1784311691,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金域医学（603882）新注册了《金域医学项目对照管理系统V1.1.3》项目的软件著作权。今年以来金域医学新注册软件著作权36个，较去年同期减少了38.98%。结合公司2025年年报财务数据，2025年公司在研发方面投入了3.41亿元，同比减14.78%。通过天眼查大数据分析，广州金域医学检验集团股份有限公司共对外投资了59家企业，参与招投标项目28次；财产线索方面有商标信息766条，专利信息222条，著作权信息197条；此外企业还拥有行政许可62个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071800000205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159180","SG9999001069.SGD","BK0284","BK0236","BK0042","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651614794","title":"金域医学上半年净利预增300%至359%；国际医学上半年预计亏损6300万元至6600万元 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2651614794","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651614794?lang=zh_cn&edition=full","pubTime":"2026-07-14 07:00","pubTimestamp":1783983650,"startTime":"0","endTime":"0","summary":"丨2026年7月14日星期二丨NO.1国际医学上半年预计亏损6300万元至6600万元7月13日，国际医学发布2026年半年度业绩预告公告，公司预计2026年半年度实现归属于母公司所有者的净利润为-6600万元至-6300万元，与上年同期的亏损1.89亿元相比，亏损有所缩窄。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607143804338663.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607143804338663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999001069.SGD","159938","BK0114","BK0077","BK0284","BK1574","BK0042","BK0096","BK0046","BK0236","603882","000516","BK0146","BK1161","09939","BK0188","BK1515","BK0181"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787003479779,"stockEarnings":[{"period":"1week","weight":-0.0614},{"period":"1month","weight":0.1016},{"period":"3month","weight":0.1088},{"period":"6month","weight":-0.0683},{"period":"1year","weight":-0.0097},{"period":"ytd","weight":0.0531}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.058},{"period":"3month","weight":-0.0448},{"period":"6month","weight":-0.0244},{"period":"1year","weight":0.0773},{"period":"ytd","weight":0.0035}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州金域医学检验集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"43126人(较上一季度增加7.68%)","perCapita":"10669股","listingDate":"2017-09-08","address":"广东省广州市海珠区国际生物岛螺旋三路10号","registeredCapital":"46325万元","survey":" 广州金域医学检验集团股份有限公司的主营业务是第三方医学检验及病理诊断业务。公司的主要产品是医学诊断服务、销售诊断产品、健康体检业务、冷链物流服务。公司参与获批国家科技重大专项4项，国家“战略性科技创新合作”重点专项1项。全年发表论文共101篇，其中SCI论文32篇，学术影响力持续提升。","listedPrice":6.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金域医学(603882)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金域医学(603882)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金域医学,603882,金域医学股票,金域医学股票老虎,金域医学股票老虎国际,金域医学行情,金域医学股票行情,金域医学股价,金域医学股市,金域医学股票价格,金域医学股票交易,金域医学股票购买,金域医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金域医学(603882)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金域医学(603882)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}